# New Psoriasis clinical trials: 171 posted since Nov 2024

Updated November 9, 2026.

171 clinical studies in psoriasis were first posted on ClinicalTrials.gov from November 15, 2024 to November 9, 2026; 64 have an industry sponsor and 117 are recruiting or about to. The newest, NCT07925957, was posted on November 9, 2026: VEGF and Nailfold Changes in Psoriasis (Al-Azhar University).

## The full list

New Psoriasis clinical trials: 171 rows for $8.55, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 7 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/psoriasis

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 171
- Industry sponsored: 64
- Recruiting or not yet: 117
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 171, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925957 | VEGF and Nailfold Changes in Psoriasis | Al-Azhar University | Observational | Completed | Psoriasis | 79 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925957) |
| November 6, 2026 | NCT07920861 | A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight... | Huabo Biopharm Co., Ltd. | Phase 1 | Recruiting | Psoriasis, Ankylosing Spondylitis | 90 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920861) |
| November 5, 2026 | NCT07918560 | Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis | Brainfarma Industria Química e Farmacêutica S/A | Not applicable | Not yet recruiting | Atopic Dermatitis, Psoriasis | 42 | Brazil | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918560) |
| November 4, 2026 | NCT07915492 | Comparison of Efficacy and Safety of Deucravacitinib Versus Methotrexate in the Treatment of Moderate-to-Severe Plaque Psoriasis . | Bangladesh Medical University | Phase 4 | Active not recruiting | Psoriasis | 106 | Bangladesh | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915492) |
| November 3, 2026 | NCT07914231 | A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis | Coultreon Biopharma | Phase 2 | Not yet recruiting | Plaque Psoriasis | 100 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914231) |
| November 2, 2026 | NCT07908641 | Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release... | Amgen | Phase 1 | Not yet recruiting | Psoriasis, Arthritis, Psoriatic, Oral Ulcer | 114 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908641) |
| October 28, 2026 | NCT07900659 | Efficacy and Flexibility of Tildrakizumab Treatment in Patients With Moderate-to-severe Plaque Psoriasis and High Disease Burden | Clin4all | Observational | Active not recruiting | Psoriasis, Moderate to Severe Psoriasis | 150 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900659) |
| October 23, 2026 | NCT07892339 | Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. | Cairo University | Phase 3 | Not yet recruiting | Psoriasis, Psoriasis Genital | 40 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892339) |
| October 21, 2026 | NCT07885345 | Definition of Novel Optoacoustic Biomarkers of Psoriasis and Psoriatic Arthritis | University of Erlangen-Nürnberg Medical School | Not applicable | Not yet recruiting | Psoriasis (PsO), Psoriasis Arthritis | 192 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885345) |
| October 5, 2026 | NCT07858591 | Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study. | Bursa Yuksek Ihtisas Training and Research Hospital | Observational | Recruiting | Arthritic Psoriasis, Psoriasis (PsO), Retinal Vessels | 135 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858591) |
| September 30, 2026 | NCT07850310 | A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001) | Merck Sharp & Dohme LLC | Phase 1 | Recruiting | Psoriasis, Healthy | 132 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850310) |
| September 30, 2026 | NCT07849101 | Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL... | Unifarco SpA | Not applicable | Not yet recruiting | Psoriasis, Psoriasis; Plaque, Psoriasis Vulgaris | 128 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849101) |
| September 29, 2026 | NCT07846813 | Evidencing Vibroacoustic Sensing for Inflammatory Skin Disease Monitoring | University of Edinburgh | Observational | Not yet recruiting | Eczema, Psoriasis | 20 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07846813) |
| September 25, 2026 | NCT07841314 | Comparative Study on Unani Formulation Vs Active Control in Plaque Psoriasis | National Institute of Unani Medicine, Bengaluru | Phase 2 | Not yet recruiting | Chronic Plaque Psoriasis, Plaque Psoriasis, Psoriasis, Taqashshur al Jild | 54 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841314) |
| September 24, 2026 | NCT07839455 | Oral and Topical Phytocannabinoids for Psoriasis | Federal University of Latin American Integration | Phase 2 | Active not recruiting | Psoriasis Vulgaris | 37 | Brazil | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839455) |
| September 14, 2026 | NCT07817394 | Patient Study to Evaluate the Safety and Emollient Performance of Doublebase Once in the Treatment of Psoriasis | Dermal Laboratories Ltd | Not applicable | Not yet recruiting | Psoriasis | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817394) |
| September 11, 2026 | NCT07816575 | Comparative Efficacy of Alpha Hydroxy Acids With and Without Nanocarriers Versus Calcipotriol Plus Betamethasone in Treatment of Plaque... | Al-Azhar University | Not applicable | Completed | Psoriasis | 80 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816575) |
| September 4, 2026 | NCT07804134 | Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in... | Medisch Spectrum Twente | Observational | Not yet recruiting | Psoriasis, Eczema/Atopic Dermatitis, Hidradenitis Suppurativa (HS) | 1,000 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804134) |
| September 3, 2026 | NCT07801495 | A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis | Novartis Pharmaceuticals | Phase 2 | Recruiting | Moderate to Severe Psoriatic Arthritis | 220 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801495) |
| August 28, 2026 | NCT07792928 | A Study of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults | Shanghai Peptidstar Therapeutics Limited | Phase 1 | Not yet recruiting | Psoriasis | 40 | New Zealand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07792928) |
| August 27, 2026 | NCT07791199 | Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers | Bristol-Myers Squibb | Phase 3 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis | 2,300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791199) |
| August 24, 2026 | NCT07780929 | A Prospective, Interventional, Exploratory Study Evaluating the Efficacy of Small-Molecule Compound XJH05 Ointment in the Treatment of... | Xijing Hospital | Not applicable | Recruiting | Psoriasis, Psoriasis (PsO) | 3 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780929) |
| August 18, 2026 | NCT07771673 | Multi-Omic SignAtures of Inflammatory Cutaneous Diseases | Guy's and St Thomas' NHS Foundation Trust | Observational | Not yet recruiting | Inflammatory Skin Conditions | 400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771673) |
| August 7, 2026 | NCT07752108 | A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis | Takeda | Phase 3 | Not yet recruiting | Palmoplantar Psoriasis | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752108) |
| August 5, 2026 | NCT07746583 | A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice | Janssen-Cilag Kft. | Observational | Recruiting | Psoriasis | 100 | Hungary | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746583) |
| August 5, 2026 | NCT07746479 | A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis ) | Livzon Pharmaceutical Group Inc. | Phase 3 | Completed | Psoriasis | 244 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746479) |
| August 4, 2026 | NCT07744191 | A Clinical Trial of Antiplatelets in Psoriasis | NYU Langone Health | Phase 4 | Not yet recruiting | Psoriasis (PsO), Psoriatic Arthritis (PsA) | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744191) |
| July 30, 2026 | NCT07736651 | Anti Inflammatory Diet With Physical Therapy on Psoriasis | Mahmoud Usama Mahmoud Ahmed | Not applicable | Completed | Psoriasis | 60 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736651) |
| July 30, 2026 | NCT07736586 | A Study of HL40626S Tablets in Healthy Adults | HighsLab Therapeutics Inc. | Phase 1 | Recruiting | Skin Disease, Immune System Disease, Skin Diseases, Papulosquamous, Psoriasis (PsO) | 64 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736586) |
| July 24, 2026 | NCT07724366 | A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Psoriasis | 400 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724366) |
| July 22, 2026 | NCT07719530 | Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Psoriasis | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719530) |
| July 20, 2026 | NCT07713212 | Combined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis | Cairo University | Phase 4 | Not yet recruiting | Psoriasis | 32 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713212) |
| July 17, 2026 | NCT07712731 | HPP737 in Adult Patients With Plaque Psoriasis | Newsoara Biopharma Co., Ltd. | Phase 3 | Completed | Psoriasis | 607 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712731) |
| July 17, 2026 | NCT07712705 | HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis. | Newsoara Biopharma Co., Ltd. | Phase 3 | Completed | Psoriasis | 515 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712705) |
| July 16, 2026 | NCT07709169 | Psoriasis and Its Impact on Quality of Life Among Psoriatic Patients | Tanta University | Observational | Completed | Psoriasis, Quality of Life | 170 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709169) |
| July 16, 2026 | NCT07707141 | Safety and Efficacy of HPP737 in Adult Patients With Plaque Psoriasis | Newsoara Biopharma Co., Ltd. | Phase 2 | Completed | Psoriasis | 123 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707141) |
| July 9, 2026 | NCT07693595 | Nailfold Capillaroscopic Changes in Psoriasis | Al-Azhar University | Observational | Recruiting | Psoriasis | 100 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693595) |
| June 17, 2026 | NCT07654751 | A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | Janssen Research & Development, LLC | Phase 4 | Recruiting | Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654751) |
| June 15, 2026 | NCT07648836 | Evaluation of Serum IL-41 Level in Patients With Ankylosing Spondylitis and Psoriatic Arthritis | Assiut University | Observational | Not yet recruiting | Ankylosing Spondylitis, Psoriasis | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648836) |
| June 15, 2026 | NCT07648602 | PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study | CorEvitas | Observational | Recruiting | Psoriasis | 2,500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648602) |
| June 11, 2026 | NCT07642544 | Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Observational | Not yet recruiting | Psoriasis, Psoriasis (PsO) | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642544) |
| June 9, 2026 | NCT07635043 | Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis | Pakistan Institute of Medical Sciences | Phase 4 | Not yet recruiting | Psoriasis (PsO) | 120 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07635043) |
| June 8, 2026 | NCT07634016 | Global Healthcare Study on Psoriasis | Julia Tatjana Maul | Observational | Recruiting | Psoriasis (PsO) | 9,600 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634016) |
| June 4, 2026 | NCT07626788 | Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis | Wasuchon Chaichan | Not applicable | Not yet recruiting | Psoriasis | 140 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07626788) |
| June 3, 2026 | NCT07623486 | Trial of HSK44459 Cream for the Management Plaque Psoriasis | Haisco Pharmaceutical Group Co., Ltd. | Phase 1/2 | Active not recruiting | Psoriasis | 180 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623486) |
| May 29, 2026 | NCT07615712 | PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study | CorEvitas | Observational | Recruiting | Psoriasis | 2,500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07615712) |
| May 29, 2026 | NCT07615257 | Managing Psychological Distress Through Mindfulness-based CBT to Evaluate Its Effectiveness on Self-compassion Among Psoriasis Patients:The... | Islamia University of Bahawalpur | Not applicable | Recruiting | Psoriasis | 128 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07615257) |
| May 18, 2026 | NCT07594054 | Inflammation Digital Biomarkers Validation Study | University of Oxford | Observational | Not yet recruiting | Psoriatic Arthritis, Psoriasis (PsO) | 3,458 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594054) |
| May 13, 2026 | NCT07582783 | A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania | Janssen Research & Development, LLC | Observational | Recruiting | Psoriasis | 200 | Romania | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582783) |
| May 12, 2026 | NCT07581418 | Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis | Pak Emirates Military Hospital | Not applicable | Not yet recruiting | Chronic Plaque Psoriasis | 88 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581418) |
| April 27, 2026 | NCT07552792 | Impact of Hand Rub Placement on Patient Trust and Disease Stigma | Huashan Hospital | Not applicable | Not yet recruiting | Noncommunicable Disease, Psoriasis | 250 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552792) |
| April 27, 2026 | NCT07552454 | Picankibart in Palmoplantar Pustulosis | Xijing Hospital | Not applicable | Recruiting | Palmoplantar Pustulosis | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552454) |
| April 24, 2026 | NCT07549828 | Sebum Metabolomics and Lipidomics for Clinical Applications | National Taiwan University Hospital | Not applicable | Not yet recruiting | Acne, Atopic Dermatitis, Seborrheic Dermatitis, Psoriasis, Healthy Subjects (HS) | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549828) |
| April 22, 2026 | NCT07546032 | Clinical Study on the Medical Device PROXERA PSOMED 30 for the Treatment of Nail Psoriasis: Evaluation of Safety and Efficacy | ICIM International S.r.l. | Not applicable | Recruiting | Nail Psoriasis | 21 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546032) |
| April 16, 2026 | NCT07532486 | A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Not applicable | Recruiting | Psoriasis | 400 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532486) |
| April 15, 2026 | NCT07530367 | Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 3 | Not yet recruiting | Palmoplantar Pustulosis (PPP) | 135 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07530367) |
| March 31, 2026 | NCT07503652 | Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis | First Hospital of China Medical University | Phase 4 | Recruiting | Palmoplantar Pustulosis (PPP) | 10 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503652) |
| March 27, 2026 | NCT07498543 | Impact of Clinical and Psychological Factors on Satisfaction With Treatment in Psoriatic Patients on Biological Therapy | Catholic University of the Sacred Heart | Observational | Completed | Psoriasis | 52 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07498543) |
| March 27, 2026 | NCT07494396 | An AI-Based Erythema Measurement System for Psoriasis Lesions | Khon Kaen University | Observational | Not yet recruiting | Psoriasis | 50 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07494396) |
| March 24, 2026 | NCT07489885 | A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis | InventisBio Co., Ltd | Phase 2 | Recruiting | Psoriasis | 75 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489885) |
| March 23, 2026 | NCT07487831 | The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease | University of California, San Francisco | Phase 4 | Recruiting | Atopic Dermatitis (Eczema), Psoriasis | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07487831) |
| March 20, 2026 | NCT07485764 | Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 | Not yet recruiting | Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis, Overweight , Obesity | 186 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485764) |
| March 18, 2026 | NCT07481019 | A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology | National University Hospital, Singapore | Not applicable | Not yet recruiting | Chronic Dermatological Conditions, Eczema, Urticaria, Psoriasis, Acne | 250 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481019) |
| March 13, 2026 | NCT07471048 | A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis | Sirt3 LLC | Not applicable | Recruiting | Psoriasis | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07471048) |
| March 6, 2026 | NCT07455578 | Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease | Seismic Therapeutic AU Pty Ltd | Phase 1 | Recruiting | Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO), Cutaneous Lupus... | 24 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455578) |
| March 5, 2026 | NCT07451626 | Clinical, Epidemiologic, and Therapeutic Characterization of Pediatric Psoriasis in the Costa Rican Social Security System | Caja Costarricense de Seguro Social | Observational | Not yet recruiting | Pediatric Psoriasis | 300 | Costa Rica | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07451626) |
| March 4, 2026 | NCT07449234 | A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis | Janssen-Cilag Ltd. | Observational | Terminated | Psoriasis | 9 | Austria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07449234) |
| March 4, 2026 | NCT07448428 | Generalized Pustular Psoriasis Registry in Costa Rica | Caja Costarricense de Seguro Social | Observational | Not yet recruiting | Generalized Pustular Psoriasis, Generalized Pustular Psoriasis (GPP) | 50 | Costa Rica | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448428) |
| March 4, 2026 | NCT07448402 | Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease | Caja Costarricense de Seguro Social | Observational | Not yet recruiting | Psoriasis, Psoriasis Arthritis, Psoriasis (PsO) | 50 | Costa Rica | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448402) |
| March 4, 2026 | NCT07448337 | Psoriasis Comorbidities at Hospital Calderón Guardia | Caja Costarricense de Seguro Social | Observational | Not yet recruiting | Psoriasis, Psoriasis Arthritis, Psoriasis (PsO), Psoriasis Patients | 350 | Costa Rica | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448337) |
| February 25, 2026 | NCT07434076 | Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional Chinese Medicine | Shanghai Yueyang Integrated Medicine Hospital | Observational | Not yet recruiting | Psoriasis, Atopic Dermatitis | 950 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07434076) |
| February 25, 2026 | NCT07432815 | Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant | Cairo University | Phase 4 | Completed | Depression, Anxiety, Psoriasis | 40 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432815) |
| February 25, 2026 | NCT07432386 | Methotrexate Versus Apremilast for Pruritus in Psoriasis | Zarmeen Khawar | Phase 4 | Not yet recruiting | Psoriasis, Pruritus | 80 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432386) |
| February 24, 2026 | NCT07430319 | Real-Life Evaluation of Guselkumab Dosing Interval Adjustments | Centre Hospitalier Universitaire de Nice | Observational | Recruiting | Psoriasis | 100 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07430319) |
| February 24, 2026 | NCT07428954 | Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care | AI Labs Group S.L | Observational | Completed | Dermatitis, Melanoma (Skin Cancer), Alopecia, Urticaria, Granuloma Annulare, Seborrheic Keratoses, Herpes, Tinea... | 16 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07428954) |
| February 24, 2026 | NCT07428915 | Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care... | AI Labs Group S.L | Observational | Completed | Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized... | 15 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07428915) |
| February 23, 2026 | NCT07426120 | Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III) | Psoriasis Research Institute of Guangzhou | Phase 3 | Recruiting | Psoriasis Vulgaris, Topical Administration, Phase III | 300 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07426120) |
| February 11, 2026 | NCT07401992 | Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | Hospital Universitario Dr. Jose E. Gonzalez | Phase 4 | Recruiting | Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2 | 62 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07401992) |
| February 5, 2026 | NCT07391423 | Assessing Psoriasis Treatment Outcomes | Wake Forest University Health Sciences | Not applicable | Not yet recruiting | Psoriasis | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07391423) |
| February 5, 2026 | NCT07390487 | The Effects of Audio-Based Therapy on Anxiety in Psoriasis | University of California, San Francisco | Not applicable | Recruiting | Psoriasis (PsO), Anxiety | 120 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07390487) |
| February 2, 2026 | NCT07382388 | A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis | Peking University Third Hospital | Observational | Not yet recruiting | Psoriasis | 70 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07382388) |
| January 29, 2026 | NCT07375654 | Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone | Cairo University | Phase 1 | Completed | Psoriasis | 32 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07375654) |
| January 27, 2026 | NCT07370766 | Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada | Chronicle Academy | Observational | Recruiting | Psoriasis (PsO), Moderate to Severe Psoriasis | 80 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07370766) |
| January 26, 2026 | NCT07366268 | Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis | Assiut University | Not applicable | Not yet recruiting | Psoriasis | 36 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07366268) |
| January 23, 2026 | NCT07362017 | Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis | Vanda Pharmaceuticals | Phase 3 | Recruiting | Moderate-to-severe Chronic Plaque Psoriasis | 300 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362017) |
| January 20, 2026 | NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | University of California, San Francisco | Phase 4 | Not yet recruiting | Psoriasis, Atopic Dermatitis | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07352566) |
| January 20, 2026 | NCT07351448 | Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its... | Shanghai Yueyang Integrated Medicine Hospital | Observational | Not yet recruiting | Psoriasis (PsO), Traditional Chinese Medicine (TCM), Diagnosis | 450 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07351448) |
| January 14, 2026 | NCT07340216 | Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis | Arcutis Biotherapeutics, Inc. | Phase 1 | Completed | Psoriasis | 22 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07340216) |
| January 13, 2026 | NCT07336641 | LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice | Fondazione ISIDE | Observational | Not yet recruiting | Psoriasis, Atopic Dermatitis, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa | 20,000 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07336641) |
| January 7, 2026 | NCT07321288 | Machine Learning-Based Prediction of Insulin Resistance in Psoriasis Patients Emphasizing Interpretability | Chinese PLA General Hospital | Observational | Active not recruiting | Psoriasis, Insulin Resistance | 1,265 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07321288) |
| January 2, 2026 | NCT07314060 | A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Terminated | Generalized Pustular Psoriasis | 36 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314060) |
| December 23, 2025 | NCT07298265 | Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis | Charite University, Berlin, Germany | Observational | Recruiting | Psoriasis (PsO), Psoriatic Arthritis (PsA) | 500 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07298265) |
| December 17, 2025 | NCT07289399 | Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS? | Cairo University | Not applicable | Recruiting | Psoriasis, Polycystic Ovary Syndrome | 40 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07289399) |
| December 8, 2025 | NCT07270003 | A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar... | Xijing Hospital | Not applicable | Recruiting | Palmoplantar Pustulosis (PPP) | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07270003) |
| December 4, 2025 | NCT07265284 | A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Phase 3 | Recruiting | Psoriasis | 104 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07265284) |
| December 3, 2025 | NCT07261306 | Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis | Lahore General Hospital | Early phase 1 | Recruiting | Psoriasis | 75 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07261306) |
| December 2, 2025 | NCT07258745 | Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and... | Chong Kun Dang Pharmaceutical | Phase 1 | Recruiting | Psoriasis | 213 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07258745) |
| December 1, 2025 | NCT07256015 | Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | Bristol-Myers Squibb | Observational | Active not recruiting | Psoriasis | 200 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07256015) |
| December 1, 2025 | NCT07255781 | Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy | University of California, San Diego | Observational | Withdrawn | Psoriasis (PsO), PsA (Psoriatic Arthritis), NAFLD (Nonalcoholic Fatty Liver Disease) | 0 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07255781) |
| November 28, 2025 | NCT07254325 | Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers | Taizhou Mabtech Pharmaceutical Co.,Ltd | Phase 1 | Completed | Psoriasis | 114 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254325) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Bristol-Myers Squibb | 7 | August 27, 2026 |
| Cairo University | 6 | October 23, 2026 |
| Xijing Hospital | 4 | August 24, 2026 |
| Caja Costarricense de Seguro Social | 4 | March 5, 2026 |
| Al-Azhar University | 3 | November 9, 2026 |
| Newsoara Biopharma Co., Ltd. | 3 | July 17, 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 3 | April 16, 2026 |
| University of California, San Francisco | 3 | March 23, 2026 |
| Shanghai Yueyang Integrated Medicine Hospital | 3 | February 25, 2026 |
| South Valley University | 3 | August 19, 2025 |
| Novartis Pharmaceuticals | 2 | September 3, 2026 |
| Janssen Research & Development, LLC | 2 | June 17, 2026 |
| Assiut University | 2 | June 15, 2026 |
| CorEvitas | 2 | June 15, 2026 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2 | June 11, 2026 |
| Haisco Pharmaceutical Group Co., Ltd. | 2 | June 3, 2026 |
| National University Hospital, Singapore | 2 | March 18, 2026 |
| Centre Hospitalier Universitaire de Nice | 2 | February 24, 2026 |
| AI Labs Group S.L | 2 | February 24, 2026 |
| Charite University, Berlin, Germany | 2 | December 23, 2025 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 65 | November 9, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 38 | November 5, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 17 | October 23, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 16 | November 6, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 16 | November 3, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 14 | November 4, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 3 | December 3, 2025 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 1 | June 3, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 1 | March 7, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 35 | November 6, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 28 | September 3, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 16 | November 9, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 9 | April 22, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 8 | October 28, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 7 | November 3, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 7 | September 30, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 7 | November 24, 2025 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 6 | December 2, 2025 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 5 | October 5, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 5 | September 30, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 5 | September 29, 2026 |
| [Hungary](https://specstream.ai/data/clinical-trials/country/hungary) | 5 | August 5, 2026 |
| [Pakistan](https://specstream.ai/data/clinical-trials/country/pakistan) | 4 | June 9, 2026 |
| Costa Rica | 4 | March 5, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 4 | October 21, 2025 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 3 | November 5, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 3 | September 4, 2026 |
| [Mexico](https://specstream.ai/data/clinical-trials/country/mexico) | 3 | February 11, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 3 | November 17, 2025 |
| [New Zealand](https://specstream.ai/data/clinical-trials/country/new-zealand) | 2 | August 28, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 2 | June 8, 2026 |
| [Thailand](https://specstream.ai/data/clinical-trials/country/thailand) | 2 | June 4, 2026 |
| [Romania](https://specstream.ai/data/clinical-trials/country/romania) | 2 | May 13, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 2 | November 18, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).